NCT07095543Recruiting
Plant-Based Online Weight Loss Through Education and Resources Program and Study
Feasibility, Implementation, and Efficacy of a Plant-based Online Weight Loss Through Education and Resources Program and Study (POWER Study)
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. Participants will meet with a physician and a registered dietitian once a week to learn about a plant-based diet and receive support and practical help in making the dietary changes. Body composition, blood sugar control, cholesterol levels, and food costs will be measured at the start and end of the study.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 15 Jul 2025
- Start date
- 2 Jan 2026
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Physicians Committee for Responsible Medicine
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07095543
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 2 Jan 2026 to the primary completion date, 1 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of recreational drugs in the past 6 months.
- Inability to maintain medication regimen as prescribed by personal healthcare provider.
Other illness
- Unstable medical or psychiatric illness.
- Current diagnosis of eating disorder.
Lab values
- Current or expected use of any weight loss medication during the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor/glucose-dependent insulinotropic polypeptide (GIP) agonists.
- Use of any weight loss medication within the 12 months preceding the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor/glucose-dependent insulinotropic polypeptide (GIP) agonists.
Other
- Pregnancy or intention to become pregnant during the study period, as verified by self-report.
- Body weight greater than 182 kg.
- Intention to follow another weight loss method during the study period.
Who the study is looking for
- U.S. men and women meeting the age of majority, defined as follows:
- Age 19 or older in Nebraska and Alabama. Age 21 or older in Puerto Rico. Age 18 or older in all other states.
- Able and willing to travel to Washington DC for a dual-energy х-rау absorptiometry (DXA) scans before and after the program.
- Able and willing to complete laboratory assessments at a local LabCorp facility before and after the program.
- Able and willing to participate in all components of the study.
- BMI of 25 or more (23 or more in persons of Asian origin).
- Access to the internet.
- English fluency.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Physicians Committee for Responsible Medicine Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.